

Hans-Joachim Böhm is Global Head of Chemistry at Roche and Center Manager for the Roche Pharma Research and Early Development Site Basel. Prior to this, Hans-Joachim Böhm was President and Research Site Head of Roche Palo Alto from October 2006 to June 2008. H…more ›

Andreas has been a memmber of the Bayer HealthCare Executive COmmittee as Head of Pharmaceuticals Reserch since February 2007. He has also been in charge of Research in the Animal Health Division since March 2011. Andreas has worked at various research institutes in Ge…more ›

Swaine Chen received his Ph.D. in Developmental Biology and an M.D. from Stanford University in 2004. He became interested in applying computational tools to infectious diseases during his post-doc in the lab of Scott Hultgren, Ph.D. at Washington University. Since 20…more ›
Chih-Liang Chin, Ph.D. is Director and Site Lead Imaging, Translational Medicine Research Centre at Merck & Sharp Dohme, Singapore. In this role, Chih-Liang provides leadership and coordination for the development of translational imaging biomarker in nonhuman prim…more ›
Professor Ceri Davies graduated from the University of Bristol with a first class honours degree and PhD in pharmacology and ran an independent academic laboratory at the University of Edinburgh before leaving academia in 1998 to join the pharmaceutical industry at Orga…more ›

Professor Elliott trained as a Paediatrician at Adelaide University and entered Academia in 1962. He undertook research training in Denver and returned as a Senior Lecturer to Adelaide. He moved to New Zealand in 1970 to become the Foundation Professor, Department of Pe…more ›

Professor Engel completed doctoral thesis in Synthetic Organic Chemistry and received Dr. rer. nat. in 1975 from Technical University of Braunschweig. After his habilitation (Dr. rer. nat. habil) in Pharmaceutical Chemistry at the University of Regensburg in 1985 he hel…more ›

Martin Everett joined MerLion in 2005, initially as Head of Biological Sciences, becoming Head of Research in 2008. Before joining MerLion he worked at Glaxo SmithKline in the UK on anti-tubercular drug discovery and led a team performing automated high throughput scree…more ›

Adam obtained his Ph.D. in the Department of Pathology at Case Western Reserve University (2004) in Cleveland, Ohio, where he studied strategies employed by Mycobacterium tuberculosis to evade detection of the CD4 T cell response. From there Adam joined the UCL Institu…more ›

Olivier Heudi obtained his diploma of advanced studies in physiology and pharmacology at Pasteur Institute Paris (France) in 1995 and his Ph.D. in life Sciences at the University of Angers France in 1999. He previously gained experience in the analytical field at GSK St…more ›

Shinichi Koizumi, Ph.D. has experience in drug discovery more than 20 years and is one of founders of RaQualia and currently serving as Head of Research and CSO. Before starting RaQualia Shinichi was responsible as Head of Biology in Pfizer Central Research Laboratorie…more ›
Michel Liuzzi, Ph.D., has served as Director, Early Discovery Program at the Institut Pasteur Korea, Seoul (Korea) since January 2011. Prior to that, he was affiliated for 6 years with Idenix Pharmaceuticals Inc., Cambridge (USA) as Senior Director Virology. There he ma…more ›

"Professor Alex Matter, M.D., is CEO of the Experimental Therapeutics Centre, A*STAR, Singapore, having spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matte…more ›

Atsushi Nagahisa, Ph.D., is a founder of RaQualia Pharma Inc. (RaQualia) and has served as President and Chief Executive Officer since the company’s launch in July 2008. He raised $111 million to start RaQualia and successfully completed IPO in July 2011 on the Osaka S…more ›

Joined the Piramal Group in 2005. Currently, the Senior Group Leader and Head – Discovery Analytical Sciences, and head of the NMR/protein NMR research facility. Working on protein-drug interaction studies by NMR and understanding the structure, conformation and dynamic…more ›

Dr. Kevin Tan pursued his PhD at the Department of Microbiology NUS and his postdoctoral studies at the Laboratory of Molecular Parasitology, The Rockefeller University, New York, under the supervision of Professor George Cross. Upon his return to Singapore in 2003, he …more ›

David Wadsworth carried out his Ph.D work at Imperial College, London, joining Ciba-Geigy in Basel as a Research Chemist in 1989. After taking on additional responsibilities in the area of managing external collaborations and compound acquisition, he took on an 18 month…more ›

Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit at Novartis, GNF/NIBR. Yuan joined Novartis in 2008. Previously, Yuan has held the following positions: 2008-2011: Novartis, Global Head and Vice President of Process Sciences & …more ›

Chihiro has more than 30 years of pharmaceutical industry experience and is a highly regarded individual of the industry. He has led the company’s global business expansion and managed several deals including the acquisition of OSI Pharmaceuticals and alliances with Amb…more ›
Drug Discovery World Asia is a strategic and scientific conference for discussing innovations, technologies and methodologies in driving drug discovery development across Asia.
It is an event that integrates academia and industry, providing broad, expert coverage of the whole drug discovery and development arena.
Co-located with BioPharma Asia Convention 2012, this is the event to attend if you're committed to drug discovery and development in Asia.